Teva Pharmaceuticals has received FDA approval and has launched a generic version of Saxenda (liraglutide), which is approved to treat adults and adolescents 12 to 17 years of age who are obese or ...

Saxenda falls outside Medicare drug plan coverage because Medicare does not cover GLP-1 agonists when doctors prescribe them specifically for weight management.

Teva is releasing a generic version of Novo Nordisk’s Saxenda, a liraglutide injection. Liraglutide injection is indicated for adults with obesity or overweight who also have weight related medical ...

Teva Pharmaceuticals has launched the first generic GLP-1 drug for weight loss in adults and adolescents; a lower-cost ...

Saxenda falls outside Medicare drug plan coverage because Medicare does not cover GLP-1 agonists when doctors prescribe them specifically for weight management.